


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE	<i>Application No.</i>	(to be assigned)
	<i>Filing Date</i>	28 September 2001
	<i>First Named Inventor</i>	Markku KOULU
	<i>Group Art Unit</i>	
	<i>Examiner Name</i>	
	<i>Attorney Docket No.</i>	2630-111
<i>Title of the Invention:</i> DIAGNOSIS OF A PERSON'S RISK FOR DEVELOPING ATHEROSCLEROSIS OR DIABETIC RETINOPATHY		

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith copies of publications that the Office may wish to consider in examination of the subject application. The publications are listed on the attached form PTO-1449.

RESPECTFULLY SUBMITTED,					
NAME AND REG. NUMBER	Jeffrey L. Ihnen, Registration No. 28,957				
SIGNATURE				DATE	28 SEPTEMBER 2001
Address	ROTHWELL, FIGG, ERNST & MANBECK Suite 701-East, 555 13th Street, N.W.				
City	Washington	State	D.C.	Zip Code	20004
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	(to be assigned) 09/937899
				Filing Date	28 September 2001
				First Named Inventor	Markku KOULU
				Group Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	2630-111

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number (if known)	Kind Code ²		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code	Number ⁴	Kind ⁵ (if known)			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	1	KARVONEN, M.K. et al. (1998). "Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels," <i>Nature Med.</i> 4(12):1434-1437.	
	2	CHEW, E.Y. et al. (1996). "Association of Elevated Serum Lipid Levels With Retinal Hard Exudate in Diabetic Retinopathy," <i>Arch. Ophthalmol.</i> 114:1079-1084.	
	3	ITO, H. et al. (1996). "Risk Factor Analyses for Macrovascular Complication in Nonobese NIDDM Patients," <i>Diabetes</i> 45(3):S19-S23.	
	4	UEDA, H. et al. (1993). "Importance of serum cholesterol level in development of diabetic autonomic neuropathy," <i>Diabetes Res. Clin. Practice</i> 21:123-126.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.